Technical Analysis for VNDA - Vanda Pharmaceuticals Inc.

Grade Last Price % Change Price Change
C 4.87 -0.61% -0.03
VNDA closed down 0.41 percent on Wednesday, November 20, 2024, on 61 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish -0.61%
MACD Bearish Signal Line Cross Bearish -0.61%
NR7 Range Contraction -0.61%
NR7-2 Range Contraction -0.61%
Narrow Range Bar Range Contraction -0.61%
Doji - Bullish? Reversal -0.61%
Down 3 Days in a Row Weakness -0.61%
Down 4 Days in a Row Weakness -0.61%
Down 5 Days in a Row Weakness -0.61%
Fell Below 200 DMA Bearish -1.02%

   Recent Intraday Alerts

Alert Time
Down 1% about 1 hour ago
Rose Above Previous Day's High about 2 hours ago
20 DMA Resistance about 2 hours ago
Down 2 % about 21 hours ago
60 Minute Opening Range Breakdown about 21 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Vanda Pharmaceuticals Inc. Description

Vanda Pharmaceuticals, Inc., a biopharmaceutical company, offers development and commercialization of products for the treatment of central nervous system disorders. The company provides Fanapt, a compound for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist that has indications for chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, alcohol dependence, anxiety, depression, and pruritus. Its product in clinical development includes Tasimelteon, which completed Phase III clinical trials for the treatment of circadian rhythm sleep disorders, as well as completed Phase IIb/III trials for the treatment of major depressive disorder and insomnia. Vanda Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Washington, District of Columbia.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Alcohol Clinical Development Oncology Organic Compounds Chemical Compounds Chemotherapy Schizophrenia Depression Central Nervous System Disorders Major Depressive Disorder Nervous System Disorders Depressive Disorder Sleep Disorders Pyridines Insomnia Nausea Treatment Of Major Depressive Disorder Sedatives Treatment Of Schizophrenia Treatment Of Central Nervous System Disorders Pruritus Chemotherapy Induced Nausea Fanapt Iloperidone

Is VNDA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.75
52 Week Low 3.46
Average Volume 651,269
200-Day Moving Average 4.97
50-Day Moving Average 4.80
20-Day Moving Average 4.91
10-Day Moving Average 5.13
Average True Range 0.21
RSI (14) 48.72
ADX 26.62
+DI 26.37
-DI 21.66
Chandelier Exit (Long, 3 ATRs) 4.91
Chandelier Exit (Short, 3 ATRs) 5.10
Upper Bollinger Bands 5.46
Lower Bollinger Band 4.37
Percent B (%b) 0.49
BandWidth 22.19
MACD Line 0.07
MACD Signal Line 0.09
MACD Histogram -0.0121
Fundamentals Value
Market Cap 281.93 Million
Num Shares 57.5 Million
EPS 0.04
Price-to-Earnings (P/E) Ratio 122.50
Price-to-Sales 1.24
Price-to-Book 0.44
PEG Ratio -2.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.05
Resistance 3 (R3) 5.04 4.98 5.03
Resistance 2 (R2) 4.98 4.94 4.99 5.02
Resistance 1 (R1) 4.94 4.92 4.95 4.95 5.01
Pivot Point 4.88 4.88 4.89 4.89 4.88
Support 1 (S1) 4.84 4.84 4.85 4.85 4.79
Support 2 (S2) 4.78 4.82 4.79 4.78
Support 3 (S3) 4.74 4.78 4.78
Support 4 (S4) 4.75